EFX vs LIXT · P/E 54, rev $5.68B vs $121.0M cap
Equifax Inc (EFX) versus Lixte Biotechnology Holdings Inc (LIXT) — a side-by-side from cached financials, not a winner call.
Equifax Inc (EFX) is a consulting services company listed on US.
Lixte Biotechnology Holdings Inc (LIXT) is a biotechnology company listed on NASDAQ.
Latest reported EFX revenue for 2024-12-31 was $5.68B. Net income was $607.3M. Revenue was up 7.9% from 2023-12-31 to 2024-12-31. EFX currently screens at market cap $33.00B and trailing P/E 54.0.
LIXT does not have a complete income-statement cache yet.
EFX currently screens at market cap $33.00B and trailing P/E 54.0. LIXT currently screens at market cap $121.0M.
Not investment advice. Open the EFX and LIXT stock pages for the full models.
Not investment advice.